Douyon R, Angrist B, Peselow E, Cooper T, Rotrosen J
Psychiatry Service, New York VA Medical Center, Manhattan.
Am J Psychiatry. 1989 Feb;146(2):231-4. doi: 10.1176/ajp.146.2.231.
Alprazolam added to stable doses of neuroleptics in nine schizophrenic patients was associated with a 20%-30% mean reduction in positive and negative symptoms, although clinical response was variable and in some patients particularly brisk. The authors examined the possibilities of a pharmacokinetic effect of alprazolam on neuroleptic plasma levels and of a clinical effect of alprazolam. The modest increase in mean neuroleptic plasma levels did not correlate with clinical change, but those patients with the highest alprazolam plasma levels tended to show more robust clinical responses.
在9名精神分裂症患者中，将阿普唑仑添加到稳定剂量的抗精神病药物中，结果显示阳性和阴性症状平均减少了20%-30%，尽管临床反应存在差异，部分患者的反应尤为迅速。作者研究了阿普唑仑对抗精神病药物血浆水平的药代动力学影响以及阿普唑仑的临床效果。抗精神病药物血浆水平的适度升高与临床变化并无关联，但阿普唑仑血浆水平最高的那些患者往往表现出更显著的临床反应。
